Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs.
D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000627:therapeutic use*; D004357:Drug Synergism; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008722:Methods; D009461:Neurologic Manifestations; D009966:Orphenadrine / Q000627:therapeutic use; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D012472:Salivation; D013375:Substance Withdrawal Syndrome; D013997:Time Factors; D014202:Tremor; D014282:Trihexyphenidyl / Q000627:therapeutic use
D010276:Parasympatholytics; D004295:Dihydroxyphenylalanine; D014282:Trihexyphenidyl; D009966:Orphenadrine